Report 3: Growth strategies in Japan’s pharma market – People - P Reed Maurer

4 December 2013

It is the people that set the Pharma industry apart from other industries. In one company you have an eclectic mix of professionals with scientific, business, legal, and manufacturing experience, comments P Reed Maurer continuing his set of exclusive articles on Growth strategies in Japan for The Pharma Letter, this time focusing on People.

Growth of pharma companies relies heavily on the quality of their people. This is true in Japan as it is elsewhere. Additionally, the industry in Japan has a very positive public image in a society that historically put a high value on the benefits of medicines and those who prescribe them.

Large Japanese companies

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >